Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Call Transcript October 30, 2024Intra-Cellular Therapies, Inc. misses on earnings expectations.
Intra-Cellular Therapies Inc. (ITCI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 3,050,000 | $223,168,500 | +2% | 3.25% |
| 2. | Perceptive Advisors Joseph Edelman | 1,622,215 | $118,697,472 | -6% | 2.51% |
| 3. | Deep Track Capital David Kroin | 1,600,693 | $117,122,707 | +5% | 3.71% |
| 4. | Suvretta Capital Management Aaron Cowen | 1,439,026 | $105,293,532 | -9% | 3.36% |
| 5. | Holocene Advisors Brandon Haley | 1,370,831 | $100,303,704 | -8% | 0.4% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.60 | 49,500 | Director | 4,743,770 | 2020-09-14 | Filing | |
| $28.08 | 21,000 | Director | 4,694,270 | 2020-09-11 | Filing | |
| $11.00 | 6,240 | Large Shareholder, Director | 4,673,270 | 2019-09-10 | Filing | |
| $10.58 | 320,095 | Large Shareholder, Director | 4,667,030 | 2019-09-10 | Filing | |
| $9.59 | 155,116 | Large Shareholder, Director | 4,346,935 | 2019-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $88.92 | 5,343 | 0 | 2024-11-13 | Filing | ||
| $88.17 | 13,371 | 5,343 | 2024-11-13 | Filing | ||
| $90.89 | 1,648 | 0 | 2024-11-12 | Filing | ||
| $89.63 | 6,116 | 1,648 | 2024-11-12 | Filing | ||
| $88.72 | 15,105 | 7,764 | 2024-11-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,457,694 | $820,600,049 | 0.06% | |
| 2. | 9,094,302 | $651,333,910 | 0.01% | |
| 3. | 8,193,544 | $586,821,618 | 0.01% | |
| 4. | 3,627,308 | $259,787,799 | 1.43% | |
| 5. | 3,066,400 | $219,615,568 | 3.35% |
News See All
10 Most Promising Mid-Cap Stocks According to Hedge Funds
September closed on a high note, opening a wealth of opportunities for investors.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q2 2024 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to Intra-Cellular Therapies Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Hedge Funds Like Intra-Cellular Therapies (NASDAQ:ITCI)
The healthcare industry is considered to be a fairly defensive sector due to its need.
7 Best Mid-Cap Healthcare Stocks To Buy Now
The healthcare industry is considered to be a fairly defensive sector due to its need.
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies' First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
5 Best Russell 2000 Stocks To Buy According To Hedge Funds
In this article, we discuss 5 best Russell 2000 stocks to buy.
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2023 Earnings Call Transcript
Intra-Cellular Therapies, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.44. Intra-Cellular Therapies, Inc.
16 Best Mid-Cap Growth Stocks To Buy Now
Investors are hopeful that small- and mid-cap stocks will experience a broader rally this year after getting hammered for most part of the previous year as all eyes remain focused on the Magnificent Seven...